736926-06-0

Upstream product

• 648905-79-7 trifluoro-methanesulfonic acid 6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-benzoyl]-naphthalen-2-yl ester 
• 5486-55-5 2,6-dimethoxylnaphthalene 
• 166975-76-4 4-(2-(piperidin-1-yl)ethoxy)benzoyl chloride 
• 648905-80-0 (2,6-dimethoxynaphthalen-1-yl)-[4-(2-piperidin-1-ylethoxy)phenyl]methanone 
• 649724-98-1 (2-hydroxy-6-methoxy-naphthalen-1-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone 
• 648905-84-4 [2-(4-methanesulfonylphenyl)-6-methoxynaphthalen-1-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methane 
• 648905-83-3 [2-(4-methanesulfonylphenyl)-6-methoxynaphthalen-1-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanol 
• 648905-81-1 [2-(4-methanesulfonylphenyl)-6-methoxynaphthalen-1-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone 

Relevant academic research and scientific papers

A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats

The design of a novel selective estrogen receptor modulator (SERM) for the potential treatment of uterine leiomyoma is described. 16 (LY2066948-HCl) binds with high affinity to estrogen receptors α and β (ERα and ERβ, respectively) and is a potent uterine

SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP

The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.